Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants
Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of its Annual General Meeting (AGM) held on March 19, 2026. In a subsequent meeting, the company’s Board of Directors formally constituted itself, appointing new leadership roles and approving equity-based compensation grants aimed at aligning employee interests with long-term corporate performance.
These developments reflect Genmab’s continued focus on strengthening corporate governance while reinforcing its commitment to attracting, retaining, and motivating talent through structured long-term incentive programs. As a leading biotechnology company known for its antibody-based therapeutics, Genmab’s strategic decisions around leadership and compensation play a critical role in sustaining innovation and growth.
Leadership Appointments Signal Governance Continuity and Expertise
As part of the board’s reconstitution, Deirdre P. Connelly was appointed as Chair of the Board of Directors, while Pernille Erenbjerg was named Deputy Chair. These appointments underscore the company’s emphasis on experienced leadership at a time when the biotechnology sector continues to evolve rapidly, driven by scientific advancements, competitive pressures, and regulatory complexities.
Deirdre P. Connelly brings extensive experience in the pharmaceutical and healthcare industries, having held senior executive roles across global organizations. Her leadership is expected to guide Genmab through its next phase of growth, particularly as the company continues to expand its oncology and immunology pipeline.
Pernille Erenbjerg, as Deputy Chair, adds further depth to the board’s expertise. Known for her strong background in corporate governance and strategic transformation, her appointment reinforces the board’s capacity to oversee complex business operations and long-term strategic initiatives.
Together, these leadership changes aim to ensure robust governance, effective oversight, and strategic continuity as Genmab advances its mission to develop innovative antibody therapies.
Equity-Based Incentives: Aligning Employees with Long-Term Value Creation
In addition to leadership updates, the Board of Directors approved the granting of equity-based incentives to employees across Genmab and its subsidiaries. Specifically, the company will award 5,213 restricted stock units (RSUs) and 4,485 warrants as part of its broader compensation framework.
Equity incentives are a cornerstone of compensation strategies in the biotechnology industry, where long development timelines and high research and development costs necessitate a strong alignment between employee contributions and shareholder value creation. By offering RSUs and warrants, Genmab aims to foster a culture of ownership and long-term commitment among its workforce.
Understanding Restricted Stock Units (RSUs)
Restricted stock units represent a form of equity compensation that grants employees the right to receive company shares at a future date, subject to certain conditions. In Genmab’s case, each RSU is awarded at no cost to the recipient and entitles the holder to receive one share of Genmab stock with a nominal value of DKK 1 upon vesting.
The fair value of each RSU has been determined based on the closing market price of Genmab shares on the date of grant, which stands at DKK 1,645.00. This valuation reflects the market’s assessment of the company’s current worth and future growth potential.
Importantly, the RSUs are subject to a three-year vesting period. Specifically, they will vest on the first banking day of the month following the completion of three years from the grant date. This structure ensures that employees remain engaged with the company over a sustained period, contributing to its long-term success.
In addition to the time-based vesting requirement, the RSUs are governed by specific conditions outlined in the company’s restricted stock unit program. These conditions may include continued employment and, in some cases, performance-related criteria, further aligning employee incentives with corporate objectives.
Warrants: A Complementary Long-Term Incentive
Alongside RSUs, Genmab has granted 4,485 warrants to employees. Warrants differ from RSUs in that they provide employees with the right, but not the obligation, to purchase company shares at a predetermined price in the future.
For this grant, the exercise price of each warrant has been set at DKK 1,645.00, matching the market price of Genmab shares at the time of issuance. Like RSUs, the warrants are awarded at no cost to employees, making them a potentially valuable component of total compensation if the company’s share price appreciates over time.
The fair value of each warrant has been calculated at DKK 530.62 using the Black-Scholes valuation model, a widely accepted financial methodology for pricing options and similar instruments. This valuation takes into account factors such as share price volatility, time to expiration, and risk-free interest rates.
Vesting and Expiry Structure of Warrants
The warrants granted by Genmab are subject to a vesting period of three years, mirroring the timeline for RSUs. Once vested, employees can exercise their warrants to purchase shares at the predetermined exercise price.
However, the warrants also come with a defined expiration period. All warrants will expire on the seventh anniversary of the grant date, providing a four-year window post-vesting during which employees can choose to exercise their rights. This extended timeframe offers flexibility while encouraging employees to consider the company’s long-term performance when making exercise decisions.
The terms and conditions governing these warrants are based on a program adopted by Genmab’s Board of Directors on February 23, 2021. This standardized framework ensures consistency, transparency, and compliance with regulatory requirements.
Strategic Importance of Long-Term Incentive Programs
The decision to grant RSUs and warrants reflects a broader trend within the biotechnology and pharmaceutical industries, where companies rely heavily on highly skilled professionals to drive innovation. Developing novel therapies—particularly in areas such as oncology and immunology—requires sustained effort over many years, often with uncertain outcomes.
By implementing long-term incentive programs, Genmab aims to:
- Attract top-tier talent in a competitive global market
- Retain key employees by providing meaningful financial incentives tied to tenure
- Align employee interests with those of shareholders
- Encourage a long-term perspective focused on sustainable growth
These programs are particularly important for companies like Genmab, where the success of the business is closely tied to the progress of its research pipeline and the commercialization of innovative therapies.
Transparency and Governance in Compensation Practices
Genmab has emphasized transparency in its compensation practices by making detailed information about its RSU and warrant programs publicly available through its investor relations website. This openness allows shareholders and stakeholders to understand how the company structures its incentive programs and how these programs align with corporate performance.
Such transparency is increasingly important in today’s corporate environment, where investors place a high value on strong governance and accountability. By clearly outlining the terms, conditions, and valuation of its equity grants, Genmab demonstrates its commitment to best practices in corporate governance.
Positioning for Future Growth
These governance and compensation updates come at a time when Genmab continues to strengthen its position as a leader in antibody-based therapeutics. The company’s innovative approach to drug development, combined with strategic partnerships and a robust pipeline, has positioned it as a key player in the global biotechnology landscape.
The appointment of experienced board leadership, coupled with the implementation of well-structured incentive programs, provides a solid foundation for future growth. By aligning leadership, employees, and shareholders around a shared vision, Genmab is well-equipped to navigate the challenges and opportunities that lie ahead.
The announcements following Genmab’s 2026 Annual General Meeting highlight the company’s dual focus on governance excellence and employee engagement. The appointment of new board leadership ensures strong strategic oversight, while the granting of restricted stock units and warrants reinforces a culture of long-term value creation.
The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.
Source Link: https://ir.genmab.com/
